Blair William & Co. IL lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 707,841 shares of the biopharmaceutical company’s stock after selling 112,322 shares during the period. Blair William & Co. IL’s holdings in Gilead Sciences were worth $41,239,000 at the end of the most recent reporting period.
Several other large investors also recently modified their holdings of GILD. Federated Hermes Inc. increased its stake in shares of Gilead Sciences by 133.1% in the third quarter. Federated Hermes Inc. now owns 5,142,381 shares of the biopharmaceutical company’s stock worth $324,947,000 after buying an additional 2,936,687 shares during the last quarter. BlackRock Inc. boosted its holdings in Gilead Sciences by 1.7% in the third quarter. BlackRock Inc. now owns 117,783,804 shares of the biopharmaceutical company’s stock worth $7,442,757,000 after purchasing an additional 1,949,534 shares during the period. DekaBank Deutsche Girozentrale boosted its holdings in Gilead Sciences by 106.0% in the third quarter. DekaBank Deutsche Girozentrale now owns 1,679,176 shares of the biopharmaceutical company’s stock worth $104,808,000 after purchasing an additional 863,916 shares during the period. KAMES CAPITAL plc boosted its holdings in Gilead Sciences by 170.5% in the fourth quarter. KAMES CAPITAL plc now owns 1,304,717 shares of the biopharmaceutical company’s stock worth $75,905,000 after purchasing an additional 822,466 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in Gilead Sciences by 4,195.2% in the fourth quarter. Assenagon Asset Management S.A. now owns 818,801 shares of the biopharmaceutical company’s stock worth $47,703,000 after purchasing an additional 799,738 shares during the period. Institutional investors and hedge funds own 76.36% of the company’s stock.
In related news, EVP Brett A. Pletcher sold 1,975 shares of the firm’s stock in a transaction on Wednesday, February 10th. The shares were sold at an average price of $67.41, for a total value of $133,134.75. Following the transaction, the executive vice president now directly owns 28,832 shares in the company, valued at approximately $1,943,565.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.13% of the company’s stock.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, February 4th. The biopharmaceutical company reported $2.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.15 by $0.04. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.06 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 30th. Investors of record on Monday, March 15th will be paid a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 12th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.68. This represents a $2.84 dividend on an annualized basis and a yield of 4.48%. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.30%.
GILD has been the subject of several research analyst reports. Robert W. Baird upped their price objective on shares of Gilead Sciences from $63.00 to $67.00 and gave the stock a “neutral” rating in a report on Wednesday, December 16th. Smith Barney Citigroup dropped their price target on shares of Gilead Sciences from $75.00 to $72.00 in a research report on Tuesday, December 22nd. Truist Financial dropped their price target on shares of Gilead Sciences from $67.00 to $625.00 in a research report on Friday, December 18th. TheStreet upgraded shares of Gilead Sciences from a “c” rating to a “b-” rating in a research report on Thursday, February 4th. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $83.00 to $87.00 and gave the company an “overweight” rating in a research report on Friday, February 5th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $94.93.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.